[针对B细胞急性淋巴细胞白血病的人性化和小鼠CD19CAR-T细胞治疗的长期随访]

M Y Du1, Y Q Zhang1, D Y Liao1

  • 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.

概括

人性化的CD19仿真抗原受体T细胞 (CAR-T) 疗法在复发性/抗拒性B细胞急性淋巴细胞白血病中显示出与小鼠CAR-T相比的安全性. 人性化的CAR-T在患有高瘤负担的患者中显示出更好的疗效,克服了抗药性.

相关概念视频